Article
This In Vivo feature examines the competitive landscape in functional precision medicine, including elive™, and the barriers limiting access. Elephas Chief Scientific Officer Hinco Gierman, PhD, discusses our approach.
Video
This video walks through our poster presented at ASCO 2026. The poster presents the latest data on the elive platform using routine core needle and forceps biopsies across multiple tumor types and clinical sites. Using live tumor fragments, we developed the elive index, a binary cytokine-based classifier of ex vivo ICI response. In a validation cohort, the elive index correctly predicted clinical benefit in 93% of patients and identified platform responders among patients negative for approved ICI biomarkers.
Video
This video provides an overview of our poster presented at AACR IO 2026. This poster characterizes cytokine responses to single agent and combination immune checkpoint inhibitors beyond PD-1 in live tumor fragments generated from resections and core needle biopsies, revealing that unique cytokine signatures are observed for individual tumor specimens, regardless of treatment condition.
Whitepaper
We describe our ex vivo platform for assessing immune checkpoint inhibitor response using live tumor tissue while preserving large areas of the contiguous native tumor microenvironment. Using a sequential treatment strategy, we mitigate tumor heterogeneity challenges exacerbated when tissue amount is scarce.
Whitepaper
This white paper introduces elive™ Edge, an automated cutting instrument used to precisely cut clinically relevant tissue form factors, such as core needle biopsies (CNBs), while preserving large contiguous areas of the native tumor microenvironment (TME).
Whitepaper
This white paper demonstrates that elive™ Method is an effective approach for measuring cytokine response to immune checkpoint inhibition (ICI) from live tumor fragments (LTFs) in a setting where tissue amount is limited, such as in core needle biopsies (CNBs).
Whitepaper
This white paper presents data demonstrating that elive™ Gel, a proprietary hydrogel, preserves features of the native tumor microenvironment (TME)
in live tumor fragments (LTFs) during ex vivo culture.
Video
